BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
New Supply-Chain Dynamics
Author(s)Jim Miller
As manufacturers move to manufacture to demand rather than to forecast, the traditional wholesaling business model is being transformed.
Advertisement
Articles in this issue
almost 23 years ago
Coprocessed Excipients for Solid Dosage Formsalmost 23 years ago
Manufacturing Execution Systemsalmost 23 years ago
State-of-the-Art Packaging Machinesalmost 23 years ago
January 2004almost 23 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersalmost 23 years ago
The Bioterrorism Actalmost 23 years ago
In the Spotlight--February 2004almost 23 years ago
January 2004Advertisement
Related to this article
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why AI Model Updates Need Change Control: AAPS PharmSci 360 2026
2
AAPS PharmSci 360 2026: IND-Enabling Studies vs Animal Data
3
From URS to Acceptance Evidence: Defining and Testing Interfaces in Pen Injector Assembly
4
PharmTech Weekly Roundup—October 23, 2026: CMC Considerations, Rare Disease Development, Standards Harmonization
5